New Study · July 6, 2026
SS-31 (Elamipretide): Trial Results and Narrow FDA Approval
Elamipretide moved from a mixed randomized trial record to a narrow accelerated approval for Barth syndrome. Those two facts require careful context.
Published by PeptideSchool Editorial Team
The molecule and the evidence program
SS-31 is a synthetic mitochondria-targeted tetrapeptide developed as elamipretide. Mechanistic studies have examined interactions with mitochondrial membranes and cardiolipin-related biology, but clinical conclusions depend on indication-specific human trials.
In the randomized Barth syndrome program, the primary double-blind period did not meet its main endpoints. Later observations and extension data added context, but an open-label extension does not restore the protections of the original randomized comparison. Both parts of the record belong in an accurate summary.
What the FDA decision means
The FDA later granted accelerated approval to Forzinity for a narrow Barth syndrome population. Accelerated approval is a real regulatory action, but it is not proof that every earlier hypothesis was confirmed. The decision applies to the named product, approved indication, labeling, and post-approval requirements.
It also does not generalize elamipretide to other mitochondrial conditions, wellness goals, compounded materials, or products sold under informal SS-31 labels. Product identity and indication remain essential.
How to read an apparent reversal
A missed randomized endpoint and a later narrow approval can coexist because regulators evaluate the full submitted record within a specific disease context. The right question is not whether the trial simply failed or the molecule simply won. It is which endpoint, population, evidence pathway, and regulatory standard supported each conclusion.
This article does not provide an amount, schedule, administration method, sourcing advice, or off-label recommendation. Educational content only. Not medical advice.
Sources
Educational content only. Not medical advice.